The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.
This eagle's-eye overview of the drug industry in 2015 provides insight into some of last year's top stories, including drug pricing, orphan drug development, the FDA's priority review voucher system, pipeline attrition, and the ongoing movement in M&A. We also take a look into the crystal ball and anticipate the new drugs that may reach the market in 2016.
['Graul|A I|AI|', 'Cruces|E|E|', 'Dulsat|C|C|', 'Tracy|M|M|']
D001688:Biological Products D017277:Drug Approval D016527:Drug Costs D055808:Drug Discovery D006801:Humans D009965:Orphan Drug Production D004364:Pharmaceutical Preparations D014481:United States D014486:United States Food and Drug Administration
Drug pricing Orphan drug FDA Priority review Voucher Discontinuations